Search research articles
Contact Us
Filters
Showing results (41-50 of 93) with videos related to
Page
of 10
Sort By:
Blood Advances
|
September 22, 2019
MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways
Minyoung Youn, Haigen Huang, Cheng Chen, et al.
Blood
|
July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
Hagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.
Blood
|
July 1, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L Greenberg, Zhuoxin Sun, Kenneth B Miller, et al.
Leukemia Research
|
August 19, 2003
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study
Athena M Cherry, Stephanie R Brockman, Sarah F Paternoster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)
Peter L Greenberg, Sandra J Lee, Ranjana Advani, et al.
American Journal of Clinical Pathology
|
April 21, 2024
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes
Nivaz Brar, Lauren Lawrence, Eula Fung, et al.
Leukemia & Lymphoma
|
February 7, 2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey
Alexander B Pine, Nora Chokr, Maximilian Stahl, et al.
Blood
|
April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905
Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Blood
|
November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 93) with videos related to
Sort By:
Page
of 10
Blood Advances
|
September 22, 2019
MMP9 inhibition increases erythropoiesis in RPS14-deficient del(5q) MDS models through suppression of TGF-β pathways
Minyoung Youn, Haigen Huang, Cheng Chen, et al.
Blood
|
July 16, 2010
Phase 2 study of romiplostim in patients with low- or intermediate-risk myelodysplastic syndrome receiving azacitidine therapy
Hagop M Kantarjian, Francis J Giles, Peter L Greenberg, et al.
Blood
|
July 1, 2009
Treatment of myelodysplastic syndrome patients with erythropoietin with or without granulocyte colony-stimulating factor: results of a prospective randomized phase 3 trial by the Eastern Cooperative Oncology Group (E1996)
Peter L Greenberg, Zhuoxin Sun, Kenneth B Miller, et al.
Leukemia Research
|
August 19, 2003
Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study
Athena M Cherry, Stephanie R Brockman, Sarah F Paternoster, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 17, 2004
Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)
Peter L Greenberg, Sandra J Lee, Ranjana Advani, et al.
American Journal of Clinical Pathology
|
April 21, 2024
p53 immunohistochemistry as an ancillary tool for rapid assessment of residual disease in TP53-mutated acute myeloid leukemia and myelodysplastic syndromes
Nivaz Brar, Lauren Lawrence, Eula Fung, et al.
Leukemia & Lymphoma
|
February 7, 2020
Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey
Alexander B Pine, Nora Chokr, Maximilian Stahl, et al.
Blood
|
April 13, 2006
Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia
Bruce D Cheson, Peter L Greenberg, John M Bennett, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 26, 2014
Prolonged administration of azacitidine with or without entinostat for myelodysplastic syndrome and acute myeloid leukemia with myelodysplasia-related changes: results of the US Leukemia Intergroup trial E1905
Thomas Prebet, Zhuoxin Sun, Maria E Figueroa, et al.
Blood
|
November 4, 2006
A phase 2 study of the farnesyltransferase inhibitor tipifarnib in poor-risk and elderly patients with previously untreated acute myelogenous leukemia
Jeffrey E Lancet, Ivana Gojo, Jason Gotlib, et al.
Page
of 10